## Biosketch:

Isabel Fabregat is Research Professor at IDIBELL (Bellvitge Biomedical Research Institute), head of the "TGF-beta and Cancer" group in IDIBELL and CIBEREHD. PhD in Biochemistry and Molecular Biology by the Autonoma University of Madrid (UAM), she initiated her independent group in the Complutense University, Faculty of Pharmacy, in 1991, after her postdoctoral period in the Imperial Cancer Research Foundation (ICRF) in London. Her research line focused on the molecular mechanisms that regulate hepatocyte proliferation and differentiation, arriving to describe the essential role played by TGF-beta in these processes. After a second period outside of Spain, in the University of California San Diego (UCSD,) in 1997-99, her research line focused on studying the TGF-beta role in liver pathologies, mainly fibrosis and cancer. In 2004, she moved to IDIBELL, where her group continues focused on analysing the role of TGF-beta, and the NADPH Oxidases as its targets, in liver pathologies.